NTLA Insider Trading

Intellia Therapeutics, Inc. (NTLA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $1.36B, listed on NASDAQ, employing roughly 377 people, carrying a beta of 1.82 to the broader market. Intellia Therapeutics, Inc. Led by John Leonard, public since 2016-05-06.

In the last 12 months, Intellia Therapeutics, Inc. insiders made 1 buy transaction and 19 sale transactions.

DateNameTypeSharesPriceValue
Nov 3, 2026LEONARD JOHN MS-Sale9,000$11.99$107.9K
Oct 28, 2026Marantz Jing L.A-Award275,061$11.26$3.1M
Oct 28, 2026Marantz Jing L.A-Award199,822$0.00$0
Oct 28, 2026Marantz Jing L.0$0.00$0
Oct 6, 2026Dube Michael PS-Sale1,864$12.43$23.2K
Aug 24, 2026LEONARD JOHN MS-Sale19,890$12.60$250.6K
Aug 24, 2026LEONARD JOHN MS-Sale2,785$13.00$36.2K
Jul 24, 2026Dulac Edward J IIIS-Sale8,111$11.25$91.2K
Jul 6, 2026Dube Michael PS-Sale2,641$16.78$44.3K
Jul 6, 2026Dulac Edward J IIIS-Sale4,677$18.00$84.2K

NTLA Insider Activity by Quarter

Reported Form 4 and Form 5 lines under NTLA's own SEC company ID, by transaction date, back to Q4 2024. Purchases and sales are code P / S (open market or private) in the company's shares; other lines are purchases and sales of other securities (options, warrants, preferred), awards, exercises, tax withholding, gifts and other acquisitions and dispositions. Later filings and amendments can change the current quarter. Earlier quarters are not shown: the filings read reach back to Apr 2, 2021, and a quarter counts only when every filing for it was read. Last refreshed Nov 4, 2026.

QuarterPurchasesBoughtSalesSoldOther Lines
Q4 2026 (so far)0N/A2$131.1K2
Q3 20260N/A5$506.6K0
Q2 20260N/A0N/A14
Q1 20261$1.4M9$797.2K13
Q4 20250N/A5$869.4K4
Q3 20251$1.0M4$153.8K0
Q2 20250N/A2$17.0K14
Q1 20250N/A11$863.1K19
Q4 20240N/A1$38.2K0

NTLA Institutional Ownership (13F)

As of Jun 30, 2026 (Q2 2026), 328 institutions reported holding 143,986,460 NTLA shares, valued at $2.44B as reported, 123.5% of its market cap (market cap of Jun 26, 2026). That is +24 institutions from the quarter before. Among managers whose reports for both quarters are comparable, 49 opened a position, 26 closed one, 140 added and 81 trimmed.

Top Holders, Q2 2026

ManagerSharesValueChange
ARK Investment Management LLC16,875,684$285.5M+2,366,437
BlackRock, Inc.15,409,023$260.7M+3,253,217
STATE STREET CORP9,234,987$156.3M+2,312,311
VANGUARD PORTFOLIO MANAGEMENT LLC7,332,401$124.1M+1,109,076
D. E. Shaw & Co., Inc.6,443,323$109.0M+715,146
VANGUARD CAPITAL MANAGEMENT LLC6,028,586$102.0M+944,481
TWO SIGMA INVESTMENTS, LP5,235,348$88.6M+529,447
FMR LLC4,773,034$80.8M+2,705,812
RA CAPITAL MANAGEMENT, L.P.4,526,926$76.6MNew
REGENERON PHARMACEUTICALS, INC.3,702,995$62.7MUnchanged

By Quarter

QuarterInstitutionsSharesValue
Q2 2026328143,986,460$2.44B
Q1 2026304110,515,250$1.42B
Q4 2025293104,303,458$939.3M
Q3 2025283104,644,723$1.81B
Q2 2025278100,168,478$939.7M
Q1 2025291101,460,922$721.5M
Q4 202429099,257,862$1.16B
Q3 202428093,845,090$1.93B
Q2 202428893,133,916$2.08B

From the SEC's Form 13F data sets: investment managers with $100 million or more in Section 13(f) securities report their holdings each quarter, up to 45 days after it ends; a restated filing replaces the original, and values are as the managers reported them (a position whose price runs about 1,000 times below other managers', from a manager whose positions mostly do, is read as reported in thousands of dollars). The same shares can be reported by more than one manager, so totals can count some twice.

ETFs Holding NTLA

FundWeight of NTLAShares (as reported)Value (as reported)Source updated
ARKK ARK Innovation ETF2.04%14,063,687$148.4MNov 13, 2026
VTI Vanguard Morningstar Total Stock Market ETF0.00%4,318,550$52.1MNov 12, 2026
XBI State Street SPDR S&P Biotech ETF0.48%4,527,077$51.7MNov 12, 2026
IWM iShares Russell 2000 ETF0.05%3,565,802$40.7MNov 12, 2026
ARKG ARK Genomic Revolution ETF1.93%3,516,891$40.1MNov 12, 2026
VB Vanguard Morningstar Small-Cap ETF0.02%3,155,708$38.1MNov 12, 2026
VBK Vanguard Morningstar Small-Cap Growth ETF0.05%1,756,609$21.2MNov 12, 2026
VXF Vanguard Extended Market ETF0.02%1,586,652$19.1MNov 12, 2026
IWN iShares Russell 2000 Value ETF0.10%1,301,942$14.9MNov 12, 2026
IBB iShares Biotechnology ETF0.10%1,034,760$11.8MNov 12, 2026
VTWO Vanguard Russell 2000 ETF0.05%800,129$9.6MNov 12, 2026
DFAS Dimensional - US Small Cap ETF0.03%794,660$9.1MNov 13, 2026
SCHA Schwab U.S. Small-Cap ETF0.04%744,496$7.9MNov 13, 2026
DFAC Dimensional - US Core Equity 2 ETF0.01%580,026$6.6MNov 13, 2026
FESM Fidelity Enhanced Small Cap ETF0.09%544,203$6.2MNov 13, 2026

From each fund's latest holdings file on record that shows NTLA's listed security itself. A file counts when its line count is consistent with the fund's reported holdings count (at most twice it plus 10, or at most 1,000 lines for a reported count of exactly 10, which the data source gives many funds as a cap), read with that file or inherited from the fund's last classified file (within 20% of its line count, read within 60 days). Funds whose line for the company could not be confirmed as NTLA's listed security, or that hold it through underlying funds (look-through), are not listed. Only long positions count: a fund is left out when any of its lines for NTLA reports a negative weight, share count or value, or none of them above zero (a short position, or figures that disagree). Shares, value and weight are as reported in each fund's file, dated by the data source's last update of that file (not the date of the positions); the weight is NTLA's share of that fund.

NTLA Congress Trades

Members of Congress and their households disclosed 5 transactions in NTLA on file (3 purchases, 2 sales) by 2 members, the latest trade on Aug 25, 2023.

MemberChamberTypeAmountTradedDisclosed
Thomas R. Carper (D-DE)SenateSale (Full)$1,001 - $15,000Aug 25, 2023Sep 5, 2023
Thomas R. Carper (D-DE)SenatePurchase$1,001 - $15,000May 22, 2023Jun 30, 2023
Thomas R. Carper (D-DE)SenatePurchase$1,001 - $15,000Nov 20, 2020Dec 2, 2020
James M. Inhofe (R-OK)SenateSale (Full)$15,001 - $50,000Oct 25, 2018Nov 8, 2018
James M. Inhofe (R-OK)SenatePurchase$15,001 - $50,000Oct 19, 2017Nov 8, 2017

From the periodic transaction reports members of the Senate and the House file under the STOCK Act, within 45 days of a trade (some file later); amounts are the ranges the reports give (a few give an exact amount), and a transaction a later report lists again is counted once. On file: House reports disclosed from Apr 10, 2023 through Nov 13, 2026; Senate reports disclosed from Jan 30, 2014 through Nov 4, 2026. The party is the member's on the trade date. A trade is listed under the company that traded under its ticker on the trade date (dated from Feb 1, 2021, unless the filing describes another company of ours; before that, only when the filing's description of the security is the company's name).

How to Read NTLA Insider Activity

Net insider sentiment skews to the sell side over the trailing twelve months: 19 sales versus 1 buys. Insider sales carry less informational weight than buys because they are often driven by liquidity, tax planning, or pre-scheduled Rule 10b5-1 trading plans rather than negative information. The transaction type alone does not say whether a sale was made on the open market or privately, or under a 10b5-1 plan; the filing's plan checkbox and footnotes do. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.

Learn how insider trading is reported and how to read the data →

Frequently asked NTLA insider trading questions

How active are NTLA insiders right now?
Over the trailing twelve months, Intellia Therapeutics, Inc. (NTLA) insiders made 1 buy transaction and 19 sale transactions. Net insider sentiment over the trailing twelve months tilts to the sell side (19 sales vs 1 buys). The transaction list above shows the most recent filings; each entry includes the insider's name, transaction type, share count, and per-share price.
What counts as an insider transaction?
Section 16 of the Securities Exchange Act requires officers, directors, and 10% beneficial-owner shareholders to disclose changes in their holdings via Form 3 (initial statement), Form 4 (subsequent transactions, filed within two business days), and Form 5 (annual catch-up). Insider transactions cover open-market purchases and sales, exercise of stock options, gifts, and grants. The "transaction type" field on each row distinguishes these subcategories.
Are NTLA insider buys a bullish signal?
Insider purchases (Type P, made on the open market or privately; the code covers both) carry more informational weight than insider sales: an insider must commit personal capital, and the SEC scrutinizes purchases under Rule 10b5-1 for material non-public information. Sales, by contrast, are often driven by liquidity, tax planning, or pre-scheduled 10b5-1 trading plans rather than negative information. Cluster buying (multiple insiders buying within a short window) is a stronger signal than isolated buys.
How do NTLA insider transactions affect options pricing?
Insider transaction data does not directly drive implied volatility, but Form 4 disclosures can move single-name IV if the size or timing is unusual (e.g. a large CEO buy ahead of an earnings window). Options markets price the marginal informational content; routine transactions under pre-scheduled plans are typically ignored. For event-driven options sizing, pair the insider transaction history with the upcoming earnings calendar.